Heart rate variability as a potential biomarker of pediatric obstructive sleep apnea resolution
Ver/ Abrir
Registro completo
Mostrar el registro completo DCAutoría
Martín Montero, Adrián
; Gutiérrez Tobal, Gonzalo César; Kheirandish Gozal, Leila; Vaquerizo Villar, Fernando; Álvarez González, Daniel; Campo Matías, Félix del; Gozal, David; Hornero Sánchez, Roberto
Fecha
2022-02Derechos
© Sleep Research Society. Published by Oxford University Press. This is a pre-copyedited, author-produced version of an article accepted for publication in Sleep following peer review. The version of record Adrián Martín-Montero, Gonzalo C Gutiérrez-Tobal, Leila Kheirandish-Gozal, Fernando Vaquerizo-Villar, Daniel Álvarez, Félix del Campo, David Gozal, Roberto Hornero, Heart rate variability as a potential biomarker of pediatric obstructive sleep apnea resolution, Sleep, Volume 45, Issue 2, February 2022, zsab214, is available online at: https://doi.org/10.1093/sleep/zsab214
Publicado en
Sleep, 2022, 45(2), zsab214
Editorial
Oxford University Press
Enlace a la publicación
Palabras clave
Biomarker
Causal mediation analysis
Frequency domain analysis
Heart rate variability
Obstructive sleep apnea
Resolution
Treatment
Resumen/Abstract
Study Objectives
Pediatric obstructive sleep apnea (OSA) affects cardiac autonomic regulation, altering heart rate variability (HRV). Although changes in classical HRV parameters occur after OSA treatment, they have not been evaluated as reporters of OSA resolution. Specific frequency bands (named BW1, BW2, and BWRes) have been recently identified in OSA. We hypothesized that changes with treatment in these spectral bands can reliably identify changes in OSA severity and reflect OSA resolution.
Methods
Four hundred and four OSA children (5–9.9 years) from the prospective Childhood Adenotonsillectomy Trial were included; 206 underwent early adenotonsillectomy (eAT), while 198 underwent watchful waiting with supportive care (WWSC). HRV changes from baseline to follow-up were computed for classical and OSA-related frequency bands. Causal mediation analysis was conducted to evaluate how treatment influences HRV through mediators such as OSA resolution and changes in disease severity. Disease resolution was initially assessed by considering only obstructive events, and was followed by adding central apneas to the analyses.
Results
Treatment, regardless of eAT or WWSC, affects HRV activity, mainly in the specific frequency band BW2 (0.028–0.074 Hz). Furthermore, only changes in BW2 were specifically attributable to all OSA resolution mediators. HRV activity in BW2 also showed statistically significant differences between resolved and non-resolved OSA.
Conclusions
OSA treatment affects HRV activity in terms of change in severity and disease resolution, especially in OSA-related BW2 frequency band. This band allowed to differentiate HRV activity between children with and without resolution, so we propose BW2 as potential biomarker of pediatric OSA resolution.
Colecciones a las que pertenece
- D50 Artículos [344]
- D50 Proyectos de Investigación [455]






